Antihyperglycemic effects of propolis mixed with mulberry leaf extract on patients with type 2 diabetes

Alternative Therapies in Health and Medicine

Volumn 10, Issue 3, 2004, Pages 78-79

  Murata, Kohji ^a,b   Yatsunami, Kazuhisa ^c   Fukuda, Eiichi ^c   Onodera, Satoshi ^d   Mizukami, Osamu ^e   Hoshino, Gen ^f   Kamei, Tsutomu ^a,g  

^a Shimane Institute of Health Science   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c TAMAGAWA UNIVERSITY   (Japan)

^d SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^e Tokyo Eisei Byoin   (Japan)

^f SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^g KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CHINESE DRUG; GLUCOSE; HEMOGLOBIN A1C; HERBACEOUS AGENT; INSULIN; MORUS ALBA EXTRACT; ORAL ANTIDIABETIC AGENT; PLANT EXTRACT; PROPOLIS; QUAPOLIS; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETES CONTROL; DIABETES MELLITUS; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HERBAL MEDICINE; HUMAN; MALE; MULBERRY; NON INSULIN DEPENDENT DIABETES MELLITUS; TRADITIONAL MEDICINE; TREATMENT OUTCOME;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MORUS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT LEAVES; PROPOLIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 2442584715     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Li SZ. Compendium of Materia Medica. Beijing: People's Medical Publishing House: 1978:2067.
2. Chen FJ, Nakashima N, Kimura I, Kimura M, Asano N, Koya S. Potentiating effects on pilocarpine-induced saliva secretion, by extracts and N-containing sugars derived from mulberry leaves, in Streptozocin-diabetic mice. Biol Pharm Bull. 1995;18(12):1676-1680.
3. Yoshikuni Y, Ezure Y, Aoyagi Y, Enomoto H. Inhibition of intestinal alpha-glucosidase and postprandial hyperglycemia by N-substituted moranoline derivatives. J. Pharmacobiodynamics. 1988;11(5):356-362.
4. Koo MH, Park YK. Investigation of flavonoid aglycones in propolis collected by two different varieties of bees in the same region. Biosci Biotech Biochem. 1997;61(2):367-369.
5. Kim JS, Kwon CS, Son KH. Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid. Biosci Biotech Biochem. 2000;64(11):2458-2461
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352 (9131):837-853
7. Bretzel RG, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998;106(5):369-372
8. Lebovitz HE. Oral Antidiabetic Agents. In: Kahan CR, Weir GC, ed. Joslin's Diabetes Mellitus. 13th ed. New York, NY: Williams & Wilkins; 1994;508-529.